Takeda Pharmaceutical Statistics
Total Valuation
Takeda Pharmaceutical has a market cap or net worth of $48.87 billion. The enterprise value is $77.73 billion.
Important Dates
The next estimated earnings date is Thursday, January 29, 2026, before market open.
| Earnings Date | Jan 29, 2026 |
| Ex-Dividend Date | Sep 30, 2025 |
Share Statistics
Takeda Pharmaceutical has 1.58 billion shares outstanding. The number of shares has increased by 0.65% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.58B |
| Shares Change (YoY) | +0.65% |
| Shares Change (QoQ) | -0.67% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 45.86% |
| Float | 1.58B |
Valuation Ratios
The trailing PE ratio is 218.67 and the forward PE ratio is 24.92.
| PE Ratio | 218.67 |
| Forward PE | 24.92 |
| PS Ratio | 1.64 |
| Forward PS | 0.01 |
| PB Ratio | 1.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 7.53 |
| P/OCF Ratio | 6.03 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 10.11, with an EV/FCF ratio of 11.98.
| EV / Earnings | 347.81 |
| EV / Sales | 2.60 |
| EV / EBITDA | 10.11 |
| EV / EBIT | 23.67 |
| EV / FCF | 11.98 |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of 0.73.
| Current Ratio | 1.37 |
| Quick Ratio | 0.65 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | 4.37 |
| Debt / FCF | 5.41 |
| Interest Coverage | 2.30 |
Financial Efficiency
Return on equity (ROE) is 0.47% and return on invested capital (ROIC) is 2.44%.
| Return on Equity (ROE) | 0.47% |
| Return on Assets (ROA) | 2.09% |
| Return on Invested Capital (ROIC) | 2.44% |
| Return on Capital Employed (ROCE) | 3.94% |
| Revenue Per Employee | $628,950 |
| Profits Per Employee | $4,710 |
| Employee Count | 47,455 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 1.24 |
Taxes
In the past 12 months, Takeda Pharmaceutical has paid $436.69 million in taxes.
| Income Tax | 436.69M |
| Effective Tax Rate | 66.00% |
Stock Price Statistics
The stock price has increased by +18.38% in the last 52 weeks. The beta is 0.03, so Takeda Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.03 |
| 52-Week Price Change | +18.38% |
| 50-Day Moving Average | 14.34 |
| 200-Day Moving Average | 14.66 |
| Relative Strength Index (RSI) | 73.24 |
| Average Volume (20 Days) | 2,372,539 |
Short Selling Information
The latest short interest is 11.65 million, so 0.74% of the outstanding shares have been sold short.
| Short Interest | 11.65M |
| Short Previous Month | 10.64M |
| Short % of Shares Out | 0.74% |
| Short % of Float | 0.74% |
| Short Ratio (days to cover) | 4.51 |
Income Statement
In the last 12 months, Takeda Pharmaceutical had revenue of $29.85 billion and earned $223.50 million in profits. Earnings per share was $0.14.
| Revenue | 29.85B |
| Gross Profit | 19.34B |
| Operating Income | 3.28B |
| Pretax Income | 661.61M |
| Net Income | 223.50M |
| EBITDA | 7.69B |
| EBIT | 3.28B |
| Earnings Per Share (EPS) | $0.14 |
Full Income StatementBalance Sheet
The company has $4.60 billion in cash and $35.08 billion in debt, giving a net cash position of -$30.47 billion or -$19.29 per share.
| Cash & Cash Equivalents | 4.60B |
| Total Debt | 35.08B |
| Net Cash | -30.47B |
| Net Cash Per Share | -$19.29 |
| Equity (Book Value) | 48.19B |
| Book Value Per Share | 30.50 |
| Working Capital | 5.28B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $8.11 billion and capital expenditures -$1.23 billion, giving a free cash flow of $6.49 billion.
| Operating Cash Flow | 8.11B |
| Capital Expenditures | -1.23B |
| Free Cash Flow | 6.49B |
| FCF Per Share | $4.11 |
Full Cash Flow StatementMargins
Gross margin is 64.80%, with operating and profit margins of 11.01% and 0.75%.
| Gross Margin | 64.80% |
| Operating Margin | 11.01% |
| Pretax Margin | 2.22% |
| Profit Margin | 0.75% |
| EBITDA Margin | 25.77% |
| EBIT Margin | 11.01% |
| FCF Margin | 21.74% |
Dividends & Yields
This stock pays an annual dividend of $0.53, which amounts to a dividend yield of 3.39%.
| Dividend Per Share | $0.53 |
| Dividend Yield | 3.39% |
| Dividend Growth (YoY) | 4.37% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 378.71% |
| Buyback Yield | -0.65% |
| Shareholder Yield | 2.74% |
| Earnings Yield | 0.46% |
| FCF Yield | 13.28% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Takeda Pharmaceutical has an Altman Z-Score of 1.14 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.14 |
| Piotroski F-Score | 6 |
